Maximum Plasma Concentration of Lenvatinib Is Useful for Predicting Thrombocytopenia in Patients Treated for Hepatocellular Carcinoma

BACKGROUND: Although lenvatinib treatment has a favorable efficacy for unresectable hepatocellular carcinoma (HCC), it is associated with adverse events (AEs) that must be closely monitored and managed. Thrombocytopenia is one of the major AEs. The aim of this study was to clarify whether thrombocyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Endo, Mizuki, Honda, Koichi, Saito, Tomoko, Shiraiwa, Ken, Sueshige, Yoshio, Tokumaru, Tomoko, Iwao, Masao, Tokoro, Masanori, Arakawa, Mie, Tanaka, Ryota, Tatsuta, Ryosuke, Seike, Masataka, Itoh, Hiroki, Murakami, Kazunari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577601/
https://www.ncbi.nlm.nih.gov/pubmed/34804279
http://dx.doi.org/10.14740/wjon1399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577601/
https://www.ncbi.nlm.nih.gov/pubmed/34804279
http://dx.doi.org/10.14740/wjon1399

Ejemplares similares